Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451488 · ClinicalTrials.gov registry record · Phase 4
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
A Phase 4 study of Melanoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02451488 is a Phase 4 study of Melanoma that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02451488, a Phase 4 study of Melanoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG GM-CSF
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02451488
The ClinicalTrials.gov registry entry for NCT02451488 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT02451488 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02451488 about?
NCT02451488 is a clinical study titled "Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma". Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
What is the current status of trial NCT02451488?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2015-05. Estimated completion is 2016-11-04.
What conditions does trial NCT02451488 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02451488?
The interventions under investigation include: Standard of Care (OTHER), GM-CSF (DRUG).
Who is sponsoring clinical trial NCT02451488?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02451488 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Can We Miss Pigmented Lesions in Psoriasis Patients?
COMPLETED · Phase 4
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.